SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

HER2, Avi-His-Tag Recombinant

Catalog: 102198
Lot: 240604-A1

Product Information

Description:	Recombinant human HER2 (human epidermal growth factor receptor 2, also known as ErbB2), encompassing amino acids 23-652 corresponding to the extracellular domain. This construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). This protein was affinity purified.
Background:	HER2 (human epidermal growth factor receptor 2), also known as erbB-2 or CD340, is a tyrosine kinase transmembrane receptor of the EFGR family of proteins. There is no known ligand, but it can form homodimers or heterodimers with other HER proteins. Once active, it activates the MAPK (mitogen-activated protein kinase) and PI3K (phosphatidylinositol-3 kinase) signaling pathways resulting in cell cycle progression and cell proliferation. HER2 overexpression is known to occur in breast, ovarian, stomach, lung adenocarcinoma, aggressive forms of uterine cancer, and gastric cancer. In 1990 the FDA approved the use of the monoclonal antibody trastuzumab (Herceptin) in breast and stomach cancer. Other approved strategies to target HER2 include ADCs (antibody-drug conjugate) and margetuximab (anti-HER2 antibody that can induce cytotoxicity). The development of treatments targeting early-stage cancer, with minimal side effects and resistance development, will bring major benefits to HER2-positive oncology patients.
Species	Human
Construct:	HER2 (23-652-Avi-His)
Concentration:	0.14 mg/ml
Expression System:	HEK293
Purity:	≥90%
Format:	Aqueous buffer solution.
Formulated In:	8 mM phosphate pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
MW:	72.5 kDa + glycans
Glycosylation:	This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Genbank Accession:	NM_004448.4
Stability:	At least 6 months at -80°C.
Storage:	-80°C
Instructions for Use:	Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
Assay Conditions:	This protein was tested by ELISA. A 96-well plate was coated with HER2, Avi-His-Tag Recombinant overnight at 4°C (50 µl/well at a concentration of 100 ng/reaction in PBS). The next day the plate was washed 3 times with PBST and blocked using 200 µl of Blocking Buffer 3 (#79743) for 2 hours at Room Temperature (RT). After removing the blocking buffer, 50 µl/well of purified Anti-HER2, Sortase-His-tag Antibody (#101689), serially diluted in 1x PP-02 Buffer, was added for 1 hour at RT. After washing, the plate was incubated for 60 minutes with anti-Fc-HRP-labeled antibody 1:1000 in Blocking Buffer 3 (50 µl/well) and washed again. Finally, 100 µl of ECL substrate was added to each well and plate was read immediately in a luminometer or microtiter-plate reader capable of reading chemiluminescence.
Applications:	Useful for binding studies.

HER2, Avi-His-Tag Recombinant

Catalog: 102198
Lot: 240604-A1

4-20% SDS-PAGE Coomassie Staining



HER2 binding to Anti-HER2 Antibody



EC_{50} = 0.0006 µM